Erythropoietin

Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.

Networked: 12227 relevant articles (925 outcomes, 1678 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Gassmann, Max: 40 articles (10/2022 - 07/2002)
2.	Juul, Sandra E: 40 articles (01/2022 - 08/2005)
3.	Brines, Michael: 39 articles (01/2022 - 01/2002)
4.	Cerami, Anthony: 36 articles (01/2022 - 01/2002)
5.	van Veldhuisen, Dirk J: 35 articles (10/2021 - 02/2004)
6.	Casadevall, Nicole: 34 articles (01/2020 - 01/2002)
7.	Prchal, Josef T: 31 articles (01/2018 - 05/2002)
8.	Macdougall, Iain C: 29 articles (12/2021 - 01/2002)
9.	Ehrenreich, Hannelore: 29 articles (01/2021 - 08/2002)
10.	Eckardt, Kai-Uwe: 28 articles (09/2022 - 01/2002)

Related Diseases

1.	Anemia 05/01/2001 - "The most promising results have been noted in the treatment of erythropoietin-resistant anemia. " 04/01/1992 - "Human recombinant erythropoietin constitutes a remarkable improvement in the treatment of uraemic anemia. " 09/04/1991 - "[Erythropoietin is highly effective in renal anemia but should be prescribed with caution]." 01/01/2020 - "Erythropoietin (EPO) hyporesponsiveness has been recognized as an important factor to poor efficacy of recombinant human erythropoietin in the treatment of renal anemia. " 01/01/2006 - "The only proven effective prevention of RBV-induced anemia is the concomitant administration of erythropoietin. "
2.	Chronic Kidney Failure (Chronic Renal Failure) 06/01/1996 - "The availability of recombinant human erythropoietin (rhuEPO) has dramatically improved the care of children with chronic renal failure (CRF). " 02/28/1985 - "Highly purified erythropoietin may be useful in the treatment of various forms of anaemia, particularly in chronic renal failure. " 01/01/1988 - "We conclude that recombinant human erythropoietin is very effective in treating the anaemia of end-stage renal failure on haemodialysis. " 06/01/2003 - "Anaemia correction with recombinant human erythropoietin (rh-EPO, epoetin) in end-stage renal disease (ESRD) patients has been associated with improved survival and quality of life, as well as lower overall treatment costs. " 04/01/1995 - "Epoetin (recombinant human erythropoietin) is now a widely available though expensive treatment for the anaemia of chronic renal failure, and is effective in more than 95% of patients. "
3.	Neoplasms (Cancer) 09/01/2016 - "Tumor-bearing rats with high dose erythropoietin led to a significant improvement on survival compared with placebo (hazard ratio: 0.43, 95%CI: 0.20-0.92, p=0.030), though low dose erythropoietin did not reach significance (hazard ratio: 0.46, 95%CI: 0.22-1.02, p=0.056). " 08/01/1998 - "The anaemia associated with cancer can be effectively treated with recombinant human erythropoietin (rHuEpo) in about 60% of the patients. " 07/01/1995 - "Recombinant human erythropoietin (r-Hu-EPO) is known to be effective in untreated cancer patients. " 05/01/2012 - "This novel long-acting erythropoietin derivative may have an advantage to inhibit tumor growth while preserving hematopoietic and tissue-protective effects." 01/01/2005 - "The purpose of this prospective study was to investigate the efficacy of preoperative administration of recombinant human erythropoietin in patients with gynecological cancer. "
4.	Ischemia 03/01/2010 - "Erythropoietin augments the efficacy of therapeutic angiogenesis induced by allogenic bone marrow stromal cells in a rat model of limb ischemia." 01/01/2013 - "This study shows short-term protective efficacy of erythropoietin on rat testicular injury after ischemia/reperfusion." 08/01/2011 - "These conditions were used to study the potential tissue-protective effects of erythropoietin (EPO) in C2C12 myotubes exposed to ischemia. " 09/01/2007 - "Previous studies have shown that erythropoietin (EPO) has protective effects against ischemia/reperfusion (I/R) injury in several tissues. " 01/01/2018 - "In short-term animal models of ischemia, erythropoietin (EPO) signaling through the heterodimeric EPO receptor (EPOR)/β-common receptor (βCR) is believed to elicit tissue protective effects. "
5.	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 02/01/2009 - "The efficacy of human recombinant erythropoietin (rEPO) in myelodysplastic syndromes (MDS) has generally been best in untransfused patients with 'refractory anaemia' according to the World Health Organization (WHO). " 06/01/1993 - "We studied the efficacy of high doses (100,000 IU intravenously (IV)/twice a week) of human recombinant erythropoietin (rHuEpo) in patients with transfusion dependent myelodysplastic syndromes (MDS). " 01/01/1995 - "Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies." 03/17/2022 - "This prospective observational study aimed to verify the efficacy of erythropoietin zeta in the treatment of patients with low-risk myelodysplastic syndrome. " 01/01/2017 - "Erythropoietin administration is associated with improved T-cell properties in patients with myelodysplastic syndromes."

Related Drugs and Biologics

1.	Iron
2.	Hemoglobins (Hemoglobin)
3.	Epoetin Alfa (Epogen)
4.	Granulocyte Colony-Stimulating Factor (G-CSF)
5.	Hormones (Hormone)
6.	Hematinics
7.	Neuroprotective Agents
8.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
9.	Cytokines
10.	Intercellular Signaling Peptides and Proteins (Growth Factors)

Related Therapies and Procedures

1.	Therapeutics
2.	Renal Dialysis (Hemodialysis)
3.	Drug Therapy (Chemotherapy)
4.	Blood Transfusion (Blood Transfusions)
5.	Peritoneal Dialysis